The Polish Pharmaceutical Market. Its Condition and Prospects for Growth until 2011 - December 2009

PMR Research in cooperation with KPMG conducted in July this year survey among senior management of the biggest pharmaceutical companies in Poland. The main objective of the study was to assess the current situation of the pharmaceutical market and to explore the market players’ predictions concerning the growth of the sector in the next two years.
The pharmaceutical market in Poland has developed dynamically in the past five years, weathering difficult market conditions. As demonstrated by the results of our study, the current economic situation linked to the global economic crisis has not affected the positive performance of the pharmaceutical sector, nor has it had an adverse effect on the optimistic mood which prevails among pharmaceutical companies in Poland. In 2008 the pharmaceutical market in Poland was worth PLN 24.1bn, which represented 11.5% growth in comparison with 2007. At present, it is among the areas of the Polish economy boasting the strongest future growth prospects. According to our forecasts, in 2009-2011 the CAGR (Compound Annual Growth Rate) will be 7.4%, whereas pharmaceutical companies expect it to reach approx. 6%. In terms of sales value, the Polish pharmaceutical market is the sixth largest in the European Union, while in terms of the rate of sales growth (as expressed in euro), it was the second fastest growing market in the EU in 2007-2008.